181 related articles for article (PubMed ID: 14647419)
1. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
Marsit CJ; Liu M; Nelson HH; Posner M; Suzuki M; Kelsey KT
Oncogene; 2004 Jan; 23(4):1000-4. PubMed ID: 14647419
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
3. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
[TBL] [Abstract][Full Text] [Related]
11. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
Gu J; Berman D; Lu C; Wistuba II; Roth JA; Frazier M; Spitz MR; Wu X
Clin Cancer Res; 2006 Dec; 12(24):7329-38. PubMed ID: 17189404
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
[TBL] [Abstract][Full Text] [Related]
14. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
17. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile.
Guzman LM; Koriyama C; Akiba S; Eizuru Y; Castillo D; Corvalan A; Aguayo FR
Biol Res; 2007; 40(3):365-72. PubMed ID: 18449464
[TBL] [Abstract][Full Text] [Related]
18. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
19. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.
Marsit CJ; Okpukpara C; Danaee H; Kelsey KT
Mol Carcinog; 2005 Oct; 44(2):146-50. PubMed ID: 16013053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]